Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pierrel s.p.a. - mepivacaina - mepivacaina

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - nimesulidum - granulat - nimesulidum 100 mg, saccharum 1804.69 mg, maydis amylum, glucosum liquidum dispersione desiccatum 8.75 mg, macrogoli aether cetostearylicus, acidum citricum, aromatica (orange), ad granulatum, pro charta. - antiphlogistikum, analgesico - synthetika

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - nimesulidum - compresse - nimesulidum 100 mg, natrii docusas, hydroxypropylcellulosum, lactosum monohydricum 153.7 mg, carboxymethylamylum natricum a, cellulosum microcristallinum, oleum vegetabile hydrogenatum, magnesii stearas, pro compresso corresp. natrium 0.194-0.155 mg. - antiphlogistikum, analgesico - synthetika

Unión Europea - italiano - EMA (European Medicines Agency)

pierre fabre medicament - propranololo cloridrato - emangioma - agenti beta-bloccanti - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Unión Europea - italiano - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - agenti antineoplastici - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pierrel s.p.a. - mepivacaina, associazioni - mepivacaina, associazioni

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - fractiones ribosomales rna - granulat - frazioni ribosomales rna 525 µg di klebsiella pneumoniae 14 % e streptococcus pneumoniae 12 % e streptococcus pyogenes 12 % e haemophilus influenzae inactivatum 2 % e klebsiella pneumoniae membrana 60 %, excipiens annuncio granulatum per 0,5 g. - immunstimulans in caso di infezioni orl e atemwegsbereich, di età 1. anni - batteri e hefepräparate

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - fractiones ribosomales rna - tabletten - frazioni ribosomales rna 525 µg di klebsiella pneumoniae 14 % e streptococcus pneumoniae 12 % e streptococcus pyogenes 12 % e haemophilus influenzae inactivatum 2 % e klebsiella pneumoniae membrana 60 %, excipiens pro compresso. - immunstimulans in caso di infezioni orl e atemwegsbereich - batteri e hefepräparate

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - osseinum-hydroxyapatit - confetti - osseinum-hydroxyapatit 200 mg corrisp. collagena 52 mg di calcio e 43 mg e fosforo rosso 20 mg e proteina 18 mg, excipiens pro compresso haze. - calciumtherapie - synthetika

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - ferro(ii) - retardtabletten - ferrum(ii) 80 mg ut ferrosi sulfas desiccatus, maltodextrinum, cellulosum microcristallinum, ammonio methacrylatis copolymerum a, ammonio methacrylatis copolymerum b, triethylis citras, talcum, glyceroli dibehenas, Überzug: hypromellosum, cellulosum microcristallinum, acidum stearicum, triethylis citras, e 172 (rubrum), e 172 (flavum), e 171, pro compresso obducto. - anemia da carenza di ferro in caso di accertata carenza di ferro - synthetika